Thinking Outside the Box: Alternative Binding Sites in the Ligand Binding Domain of Nuclear Receptors

Nerea Gallastegui,Eva Estébanez-Perpiñá

DOI: https://doi.org/10.1007/978-3-319-18729-7_10

2015-01-01

Abstract:Throughout the past years nuclear receptors (NRs) have been pharmaceutical targets for many diseases, such as cancers and metabolic diseases, due to the physiological spectrum of different cell regulation mechanisms that involve their actions e.g. cell proliferation, metabolism and homeostasis. The initial scientific focus for drug discovery in NRs has resulted in many important anticancer drugs currently available in the clinic. Yet, despite these successes the therapeutic strategy undertaken has almost exclusively focused in targeting their ligand binding pocket (LBP). However, the versatile nature of these proteins has shown the development of drug resistance to these drugs through mechanisms such as mutations in the LBP, which render antagonistic inhibitors as agonists and exacerbate disease progression. The need for new clinical antagonists with alternative mechanisms of actions has led the scientific community to explore other alternative sites such as druggable non-ligand binding pockets (non-LBPs). Here we will cover the available non-LBPs of different NRs and the current results that identify these sites as valuable druggable targeting pockets that may lead to alternative therapeutic strategies.